These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 29032004)

  • 1. TNFR2: A Novel Target for Cancer Immunotherapy.
    Vanamee ÉS; Faustman DL
    Trends Mol Med; 2017 Nov; 23(11):1037-1046. PubMed ID: 29032004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
    Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW
    Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity.
    Yang M; Tran L; Torrey H; Song Y; Perkins H; Case K; Zheng H; Takahashi H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):971-980. PubMed ID: 32202358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
    Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
    Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
    Govindaraj C; Scalzo-Inguanti K; Madondo M; Hallo J; Flanagan K; Quinn M; Plebanski M
    Clin Immunol; 2013 Oct; 149(1):97-110. PubMed ID: 23948613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
    Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
    Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNFR2-expressing CD4
    He J; Li R; Chen Y; Hu Y; Chen X
    Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors.
    Sheng Y; Li F; Qin Z
    Front Immunol; 2018; 9():1170. PubMed ID: 29892300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
    Chen Y; Jia M; Wang S; Xu S; He N
    Front Immunol; 2022; 13():835690. PubMed ID: 35251028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function.
    Nagar M; Jacob-Hirsch J; Vernitsky H; Berkun Y; Ben-Horin S; Amariglio N; Bank I; Kloog Y; Rechavi G; Goldstein I
    J Immunol; 2010 Apr; 184(7):3570-81. PubMed ID: 20181891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting TNFR2 for cancer immunotherapy: recent advances and future directions.
    Li L; Ye R; Li Y; Pan H; Han S; Lu Y
    J Transl Med; 2024 Sep; 22(1):812. PubMed ID: 39223671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy.
    Takahashi H; Yoshimatsu G; Faustman DL
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications.
    Yang S; Wang J; Brand DD; Zheng SG
    Front Immunol; 2018; 9():784. PubMed ID: 29725328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
    Salomon BL; Leclerc M; Tosello J; Ronin E; Piaggio E; Cohen JL
    Front Immunol; 2018; 9():444. PubMed ID: 29593717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNFR2 pathways are fully active in cancer regulatory T cells.
    Okuzono Y; Muraki Y; Sato S
    Biosci Biotechnol Biochem; 2022 Feb; 86(3):351-361. PubMed ID: 35015831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
    Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
    Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8+ T cells.
    Twu YC; Gold MR; Teh HS
    Eur J Immunol; 2011 Feb; 41(2):335-44. PubMed ID: 21268004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.